Our inspiration is our family. And yours.

We’re a team of scientists, doctors, and innovators. But we’re also a family, both at home and at work in our San Francisco-based headquarters. And like any tight-knit family, we’re inspired by keeping each other healthy, happy, and well.

At Pendulum, we’re passionate about finding revolutionary, safe, and effective solutions to the ailments that can be tied to our gut health. And given our backgrounds in biostatistics, microbiology, biotechnology, and medical research, we recognize that the key to discovering these solutions lies within the emerging field of microbiome science.

Our mission is to bridge nature and medicine.

We understand that whole-body health and wellness is tied to the complex ecosystem of microorganisms that is the microbiome, and that addressing imbalances in the microbiome will transform people’s lives from the inside.

Our mission is simple: We want to empower people with products and nutritional information that help them live healthy, well-balanced lives. To that end, we aim to create products that have the power and efficacy of a pharmaceutical with the safety and accessibility of a probiotic.

To live out our mission, we had to develop an entirely new thing–a medical probiotic. Medical probiotics are the bridge between nature and medicine, helping restore our bodies to their peak balance.

We understand that whole-body health and wellness is tied to the complex ecosystem of microorganisms that is the microbiome, and that addressing imbalances in the microbiome will transform people’s lives from the inside.

Our mission is simple: We want to empower people with products and nutritional information that help them live healthy, well-balanced lives. To that end, we aim to create products that have the power and efficacy of a pharmaceutical with the safety and accessibility of a probiotic.

To live out our mission, we had to develop an entirely new thing–a medical probiotic. Medical probiotics are the bridge between nature and medicine, helping restore our bodies to their peak balance.

More than a microbiome scientist, our pioneering CEO is a mom.

Colleen Cutcliffe has an impressive background leading and managing biology teams. She’s a scientist with a Ph.D. in Biochemistry and Microbiology from Johns Hopkins University and has held senior positions at bioscience and pharmaceutical firms. She’s also a mom, not to mention our CEO.

Colleen and her two co-founders, John and Jim, saw an opportunity to apply next-generation DNA sequencing technologies and microbiological assays to the emerging microbiome science space. Using these data, they could create metabolic maps of the microbiome and use systems biology to make novel insights into the microbiome. This scientific trio was uniquely positioned to bring new products to the world.

It was her role as a mom, however, that inspired her to team up with her two former colleagues and create Pendulum. Colleen’s first daughter was born eight weeks prematurely. That meant instead of heading home that day with mom and dad, Annabella was whisked away to the NICU for four weeks, receiving multiple doses of antibiotics as a precautionary measure due to her fragile state.

Though antibiotics served an important role in the early days of Annabella’s life, they also decimated her delicate microbiome. As she got older, Colleen began to notice distinct differences in Annabella’s metabolism compared to the rest of their family. She had to deal with food sensitivities in elementary school.

This led Colleen, John and Jim on their journey to find a safe solution to help her daughter and many others who struggle with chronic issues that are the result of a disrupted microbiome. And, this set the stage for the vision of the company to create a new generation of natural products that have proven efficacy.

After nearly a decade of research, Pendulum Glucose Control was born and remains a central part of Colleen and Annabella’s wellness.

Colleen Cutcliffe
CEO AND CO-FOUNDER

Colleen Cutcliffe is the Chief Executive Officer and co-founder of Pendulum. She has more than 15 years of experience leading and managing biology teams in academia, pharmaceuticals, and biotechnology. Prior to starting Pendulum, Colleen was the senior manager of biology at Pacific Biosciences and a scientist at Elan Pharmaceuticals. Colleen completed her postdoctoral studies at Northwestern’s Children’s Memorial Hospital. Colleen received her Ph.D. in Biochemistry and Molecular Biology from John Hopkins University and her B.A. in Biochemistry from Wellesley College.

“I am excited to be at Pendulum working towards unlocking the promise of the microbiome and building products to improve the health and lives of millions of people. Leading a team of world-class experts in medicine, lab science, manufacturing, finance and commercialization who work together fantastically makes my job easy.”

Jim Bullard
CTO AND CO-FOUNDER

Jim Bullard is Chief Technology Officer and co-founder of Pendulum. Prior, Jim served as a senior staff scientist at Pacific Biosciences. Prior to co-founding Pendulum, Jim completed his Ph.D. in Biostatistics at the University of California, Berkeley and his B.A. in Computing & Information Systems at Northwestern University. He has a passion for experimental design, programming languages, and taking long walks with his dog.

“I feel fortunate to be working with smart, motivated people on interesting problems. Building products that help people is incredibly motivating.”

John Eid
CSO AND CO-FOUNDER

John Eid is the Chief Science Officer and co-founder of Pendulum. John has led technology development teams for nearly two decades in diverse areas that include advanced microscopy, single molecular detection and analyses, automated data acquisition systems, biophysical systems modeling, and genome sequencing applications. Prior to co-founding Pendulum, John was a principal scientist at Pacific Biosciences. John completed his postdoctoral research at the Roland Institute at Harvard University, received his Ph.D. in Biophysics and Computational Biology at the University of Illinois, Urbana Champaign and his B.S. in Applied and Engineering Physics from Cornell University.

“It is exciting to have a front row seat on the evolution of the microbiome field from a purely academic endeavor into a field that is actually helping people in the here and now.”

Orville Kolterman
CHIEF MEDICAL OFFICER

Orville Kolterman has been the Chief Medical Officer at Pendulum since its launch. He is also an Adjunct Professor of Medicine at the University of California, San Diego. Orville has held a successful and distinguished 40 year medical career. During his 20 year tenure at Amylin, Orville served as the Chief Medical Officer, creating two of the most successful drugs, SYMLIN and BYETTA, which are among the most widely used diabetes drugs today. Before Amylin, Orville was the Program Director of the General Clinical Research Center and Medical Director of the Diabetes Center at the University of California Medical Center. Orville has served as a board member for the American Diabetes Association (ADA) and is a past President of the California Affiliate of the ADA. . Following graduation from the University of Kansas with a B.A. degree, Orville received a medical degree from Stanford University. He then completed his medical internship and residency at the University of Chicago prior to returning to Stanford for specialty training in Endocrinology and Metabolism.

"I feel blessed to have the opportunity to work with an exceptionally talented group of individuals at Pendulum pursuing further understanding of the human microbiome and discovering ways that its power can be harnessed to improve the lives of people impacted by various medical problems."

Colleen Cutcliffe
CEO AND CO-FOUNDER

Colleen Cutcliffe is the Chief Executive Officer and co-founder of Pendulum. She has more than 15 years of experience leading and managing biology teams in academia, pharmaceuticals, and biotechnology. Prior to starting Pendulum, Colleen was the senior manager of biology at Pacific Biosciences and a scientist at Elan Pharmaceuticals. Colleen completed her postdoctoral studies at Northwestern’s Children’s Memorial Hospital. Colleen received her Ph.D. in Biochemistry and Molecular Biology from John Hopkins University and her B.A. in Biochemistry from Wellesley College.

“I am excited to be at Pendulum working towards unlocking the promise of the microbiome and building products to improve the health and lives of millions of people. Leading a team of world-class experts in medicine, lab science, manufacturing, finance and commercialization who work together fantastically makes my job easy.”

Jim Bullard
CTO AND CO-FOUNDER

Jim Bullard is Chief Technology Officer and co-founder of Pendulum. Prior, Jim served as a senior staff scientist at Pacific Biosciences. Prior to co-founding Pendulum, Jim completed his Ph.D. in Biostatistics at the University of California, Berkeley and his B.A. in Computing & Information Systems at Northwestern University. He has a passion for experimental design, programming languages, and taking long walks with his dog.

“I feel fortunate to be working with smart, motivated people on interesting problems. Building products that help people is incredibly motivating.”

John Eid
CSO AND CO-FOUNDER

John Eid is the Chief Science Officer and co-founder of Pendulum. John has led technology development teams for nearly two decades in diverse areas that include advanced microscopy, single molecular detection and analyses, automated data acquisition systems, biophysical systems modeling, and genome sequencing applications. Prior to co-founding Pendulum, John was a principal scientist at Pacific Biosciences. John completed his postdoctoral research at the Roland Institute at Harvard University, received his Ph.D. in Biophysics and Computational Biology at the University of Illinois, Urbana Champaign and his B.S. in Applied and Engineering Physics from Cornell University.

“It is exciting to have a front row seat on the evolution of the microbiome field from a purely academic endeavor into a field that is actually helping people in the here and now.”

Orville Kolterman
CHIEF MEDICAL OFFICER

Orville Kolterman has been the Chief Medical Officer at Pendulum since its launch. He is also an Adjunct Professor of Medicine at the University of California, San Diego. Orville has held a successful and distinguished 40 year medical career. During his 20 year tenure at Amylin, Orville served as the Chief Medical Officer, creating two of the most successful drugs, SYMLIN and BYETTA, which are among the most widely used diabetes drugs today. Before Amylin, Orville was the Program Director of the General Clinical Research Center and Medical Director of the Diabetes Center at the University of California Medical Center. Orville has served as a board member for the American Diabetes Association (ADA) and is a past President of the California Affiliate of the ADA. . Following graduation from the University of Kansas with a B.A. degree, Orville received a medical degree from Stanford University. He then completed his medical internship and residency at the University of Chicago prior to returning to Stanford for specialty training in Endocrinology and Metabolism.

"I feel blessed to have the opportunity to work with an exceptionally talented group of individuals at Pendulum pursuing further understanding of the human microbiome and discovering ways that its power can be harnessed to improve the lives of people impacted by various medical problems."

We’re honored to serve alongside our prestigious board members.

Board of Directors

Adam D’augelli Adam D’augelli

Adam D’augelli

Partner
True Ventures

Colleen Cutcliffe Colleen Cutcliffe

Colleen Cutcliffe

CEO
pendulum therapeutics

Craig Sherman, General Partner Craig Sherman, General Partner

Craig Sherman, General Partner

Meritech Capital

Heather Mason Heather Mason

Heather Mason

Fmr. SVP
Abbott Nutrition

Fmr. SVP
Abbott Diagnostics

Hugh Martin Hugh Martin

Hugh Martin

CEO
Lacuna Technologies
Sensity Biosystems (acq Verizon)
Pacific Biosciences (IPO)
ONI Systems (IPO)

John Eid John Eid

John Eid

CSO
pendulum therapeutics

Peter Barton Hutt, Senior Counsel Peter Barton Hutt, Senior Counsel

Peter Barton Hutt, Senior Counsel

Senior Counsel
Covington & Burling

Fmr. General Counsel
FDA

Roelof Botha Roelof Botha

Roelof Botha

Seed & Early, Growth Partner
Sequoia Capital

Medical Advisory Board

Anne Peters, MD Anne Peters, MD

Anne Peters, MD

DIRECTOR, CLINICAL DIABETES
UNIVERSITY OF SOUTHERN CALIFORNIA PRIVATE PRACTICE

Carol Wysham, MD Carol Wysham, MD

Carol Wysham, MD

PROFESSOR
UNIVERSITY OF WASHINGTON

PRACTITIONER
ROCKWOOD MULTICARE CENTER FOR DIABETES

Davida Krueger, NP Davida Krueger, NP

Davida Krueger, NP

NURSE PRACTITIONER
HENRY FORD HEALTH SYSTEM

CHAIR
AMERICAN DIABETES ASSOCIATION (ADA) RESEARCH FOUNDATION

Emeran Mayer, MD Emeran Mayer, MD

Emeran Mayer, MD

DIRECTOR, OPPENHEIMER CENTER FOR NEUROBIOLOGY OF STRESS AND RESILIENCE

PROFESSOR, DEPARTMENT OF MEDICINE
UCLA

Jay Pasricha, MD Jay Pasricha, MD

Jay Pasricha, MD

DIRECTOR, NEUROGASTROENTEROLOGY VICE CHAIR, MEDICINE INNOVATION AND COMMERCIALIZATION
JOHNS HOPKINS UNIVERSITY

John Buse, MD John Buse, MD

John Buse, MD

CHAIR, DIVISION OF ENDOCRINOLOGY
UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE

Linda Nguyen, MD Linda Nguyen, MD

Linda Nguyen, MD

ASSOCIATE PROFESSOR, GASTROENTEROLOGY AND HEPATOLOGY
STANFORD UNIVERSITY

Purna Kashyap, MBBS Purna Kashyap, MBBS

Purna Kashyap, MBBS

ASSOCIATE PROFESSOR, MEDICINE
MAYO CLINIC

Robert Ratner, MD Robert Ratner, MD

Robert Ratner, MD

CHIEF MEDICAL OFFICER
VIRTA HEALTH

FMR CHIEF SCIENTIFIC & MEDICAL OFFICER
AMERICAN DIABETES ASSOCIATION

Scientific Advisory Board

Alfred Spormann, Ph.D. Alfred Spormann, Ph.D.

Alfred Spormann, Ph.D.

PROFESSOR, CIVIL AND ENVIRONMENTAL ENGINEERING
STANFORD UNIVERSITY

Christopher Mason, Ph.D. Christopher Mason, Ph.D.

Christopher Mason, Ph.D.

Professor
WEILL Cornell medicine

Director of Emerging Genome Technologies
Tempus Labs, Inc.

Dietrich Stephan, Ph.D. Dietrich Stephan, Ph.D.

Dietrich Stephan, Ph.D.

CEO
NEUBASE THERAPEUTICS

CHAIR, DEPARTMENT OF HUMAN GENETICS
UNIVERSITY OF PITTSBURGH

Eric Schadt, Ph.D. Eric Schadt, Ph.D.

Eric Schadt, Ph.D.

FOUNDER & CEO
SEMA4

DEAN FOR PRECISION MEDICINE
Icahn School of Medicine at Mount Sinai

Peter Turnbaugh, Ph.D. Peter Turnbaugh, Ph.D.

Peter Turnbaugh, Ph.D.

ASSISTANT PROFESSOR, DEPARTMENT OF MICROBIOLOGY AND IMMUNOLOGY
UCSF

Investors
Early Supporters

Join our team

Inspired by our mission? We’re always on the lookout for the best and brightest to help bring innovative microbiome solutions to life.

See Open Roles